Cómo citar
Jaramillo TrujilloG., MejíaJ. J., GómezL. F., JaramilloM. A., & CaballeroD. (2020). Porfirias agudas: manifestaciones inespecíficas y manejo terapéutico específico. Revista Repertorio De Medicina Y Cirugía, 29(1). https://doi.org/10.31260/RepertMedCir.v29.n1.2020.886

Autores/as

Gilberto Jaramillo Trujillo
José Julián Mejía
Luis Fernando Gómez
María Andrea Jaramillo
Dayana Caballero

Resumen

Revisión clínica, científica, teórica y documental teniendo como objetivo principal realizar una revisión sobre la porfiria aguda, su enfoque, diagnóstico y tratamiento. Se utilizó una metodología descriptiva, cualitativa y teórica que permitió la revisión bibliográfica de los estudios relacionados con la porfiria aguda, trastorno congénito poco frecuente que causa alteraciones en las enzimas de la biosíntesis del grupo hem. La importancia de esta patología radica en que se confunde con otras enfermedades debido al cuadro clínico complejo difícil de identificar, lo que ocasiona un diagnóstico tardío que puede comprometer la vida del paciente y por ello se conoce como enfermedad silenciosa. Como conclusión se recomienda mayor atención a los factores precipitantes de los ataques agudos por la elevada morbimortalidad, así como hacer un diagnóstico rápido y oportuno por medios cualitativos y cuantitativos solicitando PBG (porfobilinógeno) y ALA (ácido delta aminolevulínico).

Licencia

Citas

1. Bonkovsky H; Guo J. et al. Porphyrin and Heme Metabolism and the Porphyrias. Comprehensive Physiology 2013; Volume 3, pg 376-7.

2. Bissell M. and Wang B. Acute Hepatic Porphyria. Journal of Clinical and Translational Hepatology 2015 vol. 3 Pages: 17-26.

3. Bonkovsky HL; Cable EE; Cable JW; Donohue SE; White EC; Greene YJ; Lambrecht RW; Srivastava KK. and Arnold WN. Porphyrogenic properties of the terpenes camphor, pinene, and thujone (with a note on historic implications for absinthe and the illness of Vincent van Gogh). Biochem Pharmacol 43: 2359-2368, 1992.

4. Winkler MG. and Anderson KE. Vampires, porphyria, and the media: Medicalization of a myth. Perspect Biol Med 33: 598-611, 1990.

5. Siegesmund M; Poblete-Gutiérrez P. et al. The acute hepatic porphyrias: Current status and future
challenges. Best Practice & Research Clinical Gastroenterology 2010; 24: 593–605.

6. Besur S. and Schmeltzer P, et al. ACUTE PORPHYRIAS. The Journal of Emergency Medicine 2015; Vol. 49, No. 3, pp. 305–312.

7. Meissner PN; Dailey TA; Hift RJ; Ziman M; Corrigall AV; Roberts AG. et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996;13:95–97. doi: 10.1038/ng0596-95.

8. Puy, H.; Gouya, L. and Deybach J.C. Porphyrias. Lancet 2010, 375, 924–937. LATORRE G, MUNOZ A. Porfiria intermitente aguda: Hospital Universitario San Vicente de Paúl (1974-1987). Acta Méd Colomb. 1988;13:443-51.

9. Fuller S. and Wiley J. Heme Biosynthesis and Its Disorders. Hematology: Basic Principles and Practice, Chapter 36, 2013; 457-472.e5.

10. Chiabrando D; Mercurio S. and Tolosano E. Heme and erythropoieis: more than a structural role. Haematologica. 2014 Jun;99(6):973-83.

11. Furuyama K. and Sassa S: Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia. J Clin Invest 105:757, 2000.

12. Shaw GC; Cope JJ; Li L. et al: Mitoferrin is essential for erythroid iron assimilation. Nature 440:96, 2006.

13. Sassa S; Hematologic aspects of the porphyrias. Int J Hematol 71:1, 2000.

14. Besur; Hou W; Schmeltzer P. and Bonkovsky H. Clinically Important Features of Porphyrin and Heme Metabolism and the Porphyrias. Metabolites 2014, 4, 977-1006.

15. Pischik E. and Kauppinen R. An update of clinical management of acute intermittent porphyria. The Application of Clinical Genetics 2015:8 201–214.

16. Simon N. and Herkes G. The neurologic manifestations of the acute porphyrias. Journal of Clinical
Neuroscience 18 (2011) 1147–1153.

17. Hermes-Lima M; Castilho RF; Valle VG. et al. Calcium-dependent mitocondrial oxidative damage promoted by 5-aminolevulinic acid. Biochim Biophys Acta 1992;1180:201–6.

18. Felitsyn N; McLeod C; Shroads AL; et al. The heme precursor deltaaminolevulinate blocks peripheral myelin formation. J Neurochem 2008;106:2068–79.

19. Percy VA; Shanley BC. Studies on haem biosynthesis in rat brain. J Neurochem 1979;33:1267–74.

20. Lin CS, Krishnan AV, Lee MJ, et al. Nerve function and dysfunction in acute intermittent porphyria. Brain 2008;131:2510–9.

21. Horn S; Quasthoff S; Grafe P. et al. Abnormal axonal inward rectification in diabetic neuropathy. Muscle Nerve 1996;19:1268–75.

22. Kauppinen R; Mustajoki P. Prognosis of acute porphyria: Occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltim.) 1992, 71, 1–13.

23. Herrick A. and McColl K. Acute intermittent porphyria. Best Practice & Research Clinical Gastroenterology 2005; Vol. 19, No. 2, pp. 235–249.

24. Balwani M. and Desnick R. The porphyrias: advances in diagnosis and treatment. Blood, 2012; Vol 120(23): 4496- 504.

25. Hasanoglu A; Balwani M; Kasapkara CS. et al. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis. 2011;34(1):225-231.

26. Chemmanur AT; Bonkovsky HL. Hepatic porphyrias: Diagnosis and management. Clin Liver Dis 8: 807-838, viii, 2004.

27. Ventura P; Cappellini MD; Biolcati G; et al., A challenging diagnosis for potential fatal diseases: Reccomendations for diagnosing acute porphyrias. European Journal of Internal Medicine. (2014); 497-505.

28. Anderson KE; Bloomer JR; Bonkovsky HL; Kushner JP; Pierach CA; Pimstone NR; et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439–50.

29. Elder GH; Hift RJ; Meissner PN. The acute porphyrias. Lancet 1997; 349:1613–7.

30. Montgomery D; and Wang B. Acute Hepatic Porphyria. Journal of Clinical and Translational Hepatology 2015; vol. 3 | 17–26.

31. Hift RJ; Peters TJ; Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the ‘Royal Malady’. J Clin Pathol 2012; 65:200–5.


32. Sassa S. ALAD porphyria. Semin Liver Dis 1998; 18:95–101.

33. Herman DS; Geraldine M; Venkatesh T. Evaluation, diagnosis, and treatment of lead poisoning in a patient with occupational lead exposure: a case presentation. J Occup Med Toxicol 2007; 2:7.

34. Hebert L. Bonkovsky Neurovisceral porphyrias: what a hematologist needs to know. Am Soc of Hemat. 2005:4:24-30.

35. Pischik E; Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-Grand) 2009; 55:72–83.

36. Crimlisk HL. The little imitator–porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997; 62:319–28.

37. Hindmarsh JT. The porphyrias, appropriate test selection. Clin Chim Acta 2003; 333:203–7.
38. Smith KM; Guillard R; editors. The porphyrin handbook. St Louis: Elsevier; 2003. p. 211–45.

39. Elder GH; Hift RJ. Treatment of acute porphyria. Hosp Med 2001; 62:422–5.

40. Disler PB; Eales L. The acute attack of porphyria. S Afr Med J 1982; 61:82–4.

41. Zoubida Karima; Said Lyoumi; et al. Porphyrias: A 2015 update. Clinics and Research in Hepatology and Gastroenterology (2015) 39, 412—425.

42. Lai CK; Lam CW; Chan YW. High-performance thin-layer chromatography of free porphyrins for diagnosis of porphyria. Clin Chem 1994; 40:2026–9.

43. Sardh E; Andersson DE; Henrichson A; Harper P. Porphyrin precursors and porphyrins in three patientswith acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-Grand) 2009; 55:66–71.

44. With TK. Simple and rapid screening for acute porphyria—‘porphobilistix’ and Hoesch test. S Afr Med J 1971:229–30.

45. Deacon AC; Peters TJ. Identification of acute porphyria: evaluation of a comercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998; 35:726–32.

46. McEwen J; Paterson C. Drugs and false-positive screening tests for porphyria. Br Med J 1972; 1:421.

47. Frith D; Yeung K; Thrush S; Hunt BJ; Hubbard JG. Lead poisoning—a differential diagnosis for abdominal pain. Lancet 2005; 366:2146.

48. Akagi R; Inoue R; Muranaka S; Tahara T; Taketani S; Anderson KE. et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol 2006; 132:237–43.

49. De RooijWM; Edixhoven A; Wilson JH. Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guillard R, editors. The porphyrin handbook. St Louis: Elsevier; 2003. p. 211–45.

50. Sardh E; Harper P; Andersson DE; Floderus Y. Plasma porphobilinogen as a sensitive biomarker tomonitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med 2009; 20:201–7.

51. Erlandsen EJ; Jorgensen PE; Markussen S; Brock A. Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest 2000; 60:627–34.

52. Di Pierro E; Brancaleoni V; Besana V; Cappellini MD. Multiplex ligation-dependent probe amplification: a novel approach for genetic diagnosis of Porphyria. J Hum Genet 2009; 54:479–87.

53. De Siervi A; Varela LS; Parera VE; Batlle AM; Rossetti MV. Diagnosis of latent acute intermittent porphyria by genetic analysis. Ann Clin Biochem 2001; 38:149–52.

54. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993; 153: 2004–08.

55. Stein P; Badminton M. y cols. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Annals of Clinical Biochemistry 2013; 50: 217–223.

56. R J Desnic; Balwani M. Inherited Porphyrias. Chapter 99. Elsevier 2013.

57. Marsden J. T; Guppy S. Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. SSIEM and Springer-Verlag Berlin Heidelberg 2015.

58. Ross Jones S; Bell A. Treatment of acute intermittent porphyria in the emergency department. J emerg nurs 2014;40:257-9.

59. López O; Lemus E. Porfiria intermitente aguda: presentación de un caso y revisión de la literatura. Acta Colombiana de Cuidado Intensivo 2008; 8(2): 110-115.

60. González W; Rodríguez J. Manejo médico y farmacológico del status epiléptico. Acta Neurológica Colombiana, 2011; 27:39 – 46.

61. Madhur Mehta; Girija P; Rath y cols. Intensive care management of patients with acute intermittent porphyria: Clinical report of four cases and review of literature. Indian J Crit Care Med April-June 2010 Vol. 14 Issue 2.

62. Harrison JC; McAuley FT. Propofol for sedation in intensive care in a patient with an acute porphyric attack. Anaesthesia 1992; 47:355-6.

63. Pandey CK; Singh N; Bose N; Sahay S. Gabapentin and propofol for treatment of status epilepticus in acute intermittent porphyria. J Postgrad Med 2003;49:285-5

64. Yandel ML; Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin Neurol Neurosurg 1995;97:261–263.

65. Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol 2005;28:243–4.

66. Robert TL; Varella L; Meguid MM. Nutrition management of acute intermittent porphyria. Nutrition. 1994; 10: 551.

67. Bonkovsky HL; Healey JF; Lourie AN; Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991; 86: 1050–56.

68. Anderson KE; Bonkovsky HL; Bloomer JR and Shedlofsky SI. Reconstitution of hematin for intravenous infusion. Ann Intern Med 2006; 144: 537–38.

69. Mendenhall DW. Instability of hematin solutions. N Engl J Med 1984; 311: 539–540. doi: 10.1056 /NEJM 1984 08233110819.

70. Goetsch, CA. and Bissell, DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med 1986; 315:235–238. doi: 10.1056/NEJM 198607243150406.

71. Badminton, MN; Deybach, JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 2006; 13: 668–69.

72. Pischik, E; Kauppinen, R. Can pregnancy stop cyclical attacks of porphyria? Am J Med 2006; 119: 88–90.

73. Tenhunen, R; Mustajoki, P. Acute porphyria: treatment with heme. Semin Liver Dis 1998 ;18 : 53–5

74. Sardh, E; Rejkjaer, L y cols. Pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet 2007; 46: 335–49.

75. Jeans, JB; Savik, K; Gross, CR; Weimer, MK et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996; 65:269–273.

76. Andant, C; Puy, H; Bogard, C; et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000;32:933–9.

Descargas

La descarga de datos todavía no está disponible.
Coordinador Editorial

Leonardo Arismendy Rodriguez
jlarismendy@fucsalud.edu.co
Fundación Universitaria de Ciencias de la Salud - FUCS
Bogotá DC, Colombia
Dirección: Carrera 19 No. 8 A 32
Tel: (+571) 3538100 Ext. 2836

Asistente Editorial

Gloria Restrepo B.
revista.repertorio@fucsalud.edu.co
Fundación Universitaria de Ciencias de la Salud - FUCS
Bogotá DC, Colombia
Dirección: Carrera 19 No. 8 A 32
Tel: (+571) 3538100 Ext. 2836


Vigilada Mineducación

Sistema OJS 3 - Metabiblioteca |